Purchase Order 75N95021P00714

Award Date 9/29/21
Potential Completion Date 9/29/22
Potential Value $11K
Contracting Federal Agency
National Institute on Drug Abuse
Ultimate Awardee
Not listed
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
China
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
2
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $35,600 firm fixed price purchase order contract awarded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Pharmaron, Inc., a minority-owned for-profit organization, to conduct a mouse study evaluating NNMT inhibitors in high grade serous ovarian cancer. The work, which has a 12-month period of performance, involves formulating compounds, developing a mouse model, conducting efficacy studies, and analyzing samples. No set-aside...
This firm fixed-price purchase order contract, valued at $54,000.00, was awarded by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of Health (NIH), to Pharmaron, Inc. Pharmaron is a minority-owned, for-profit Subcontinent Asian (Asian-Indian) American contract research organization that specializes in preclinical drug discovery and development services. The contract is for testing 20 small molecule compounds in rat pharmacokinetic...
This is a firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to Pharmaron, Inc.'s Phamaron Inc. Division. The contract, valued at $23,040.00, is for a pharmacokinetics assessment of eight novel compounds in mice and rats. Pharmaron is a global contract research organization (CRO) that specializes in preclinical research services, including pharmacokinetics assessments, toxicity...
This is a firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. for $24,624.00. The contract is to obtain pharmacokinetic exposure data from mouse PK studies and plasma protein binding assays, which are common preclinical services provided by Pharmaron, a global contract research organization (CRO) specializing in drug discovery and development. This contract...
The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $45,717 firm fixed price purchase order to Xenotech LLC, doing business as Sekisui-Xenotech, for the provision of cryopreserved human, mouse, and rat hepatocytes. The solicitation sought these hepatocytes for use in drug metabolism experiments to support the National Institute on Drug Abuse's malaria research project and understand drug metabolism in...
This is a $249,167.58 firm fixed price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Gempharmatech LLC, a foreign-owned for-profit biotech company. The contract is for the development of humanized mouse models for nicotinamide N-methyltransferase (NNMT) and sulfotransferase (SULT1A1) using CRISPR knock-in technology. The contractor will conduct biochemical testing of inhibitors and...
The National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services (HHS), has awarded a $124,200.00 firm fixed-price purchase order contract to Pharmaron, Inc., a minority-owned business based in China, to evaluate the pharmacokinetics of compounds from dystonia in mice, dogs, and rats. This sole-source contract, awarded under simplified acquisition procedures, will require Pharmaron to provide consistency and...
This firm fixed-price purchase order contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Heart, Lung, and Blood Institute to Pharmaron, Inc., a minority-owned for-profit contract research organization, to conduct Good Laboratory Practice (GLP) toxicity studies in rats and dogs. The $102,250.00 contract supports the Institute's Investigational New Drug (IND) enablement project, with Pharmaron performing services such as...
This is a federal contract awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the Department of Health and Human Services (HHS), to Cyprotex US LLC, a leading contract research organization specializing in predictive toxicology and ADME (absorption, distribution, metabolism, and excretion) research. The $18,024.00 firm fixed-price purchase order contract is for the testing of two compounds against key ADME and DMPK (drug metabolism and...
This is a firm fixed-price purchase order awarded by the National Institutes of Health (NIH) to Pharmaron, Inc. for $75,600 to conduct ion channel block, IC50 determination testing on 60 compounds over a period of 12 months. The work supports drug discovery and development efforts for the National Center for Advancing Translational Sciences (NCATS) and involves evaluating compounds for potential cardiotoxicity. The contract does not have a set-aside designation. Pharmaron is a global contract...

THIS REQUIREMENT IS FOR THE TESTING OF FOUR (4) SMALL MOLECULE COMPOUNDS IN MOUSE PHARMACOKINETIC STUDIES.

Posted 9/29/21, 12:00 AM